Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

2.

Year in Review: Chronic Lymphocytic Leukemia

3.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

4.

Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL

5.

Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot